Ramucirumab
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
HTNGLOMTMA
ModerateOpen →
VEGFR/EGFR/RET TKI
Vandetanib
Caprelsa · Vande
A VEGFR/EGFR/RET inhibitor for medullary thyroid cancer whose antiangiogenic action commonly raises blood pressure.
ModerateVEGFR/EGFR/RET inhibitor · approved 2011
Advanced or metastatic medullary thyroid carcinoma
Signature kidney injury
Hypertension
Representative incidence32%
In the pivotal phase III ZETA trial, any-grade hypertension occurred in about 32% of vandetanib-treated patients versus 5% with placebo; proteinuria occurs as an antiangiogenic class effect.
Source: Wells et al., J Clin Oncol 2012 (ZETA, any-grade hypertension)
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
0%incidence
SeverityModerate
ReversibilityReversible
Evidence0 refs
Nephron map
GlomerulusFiltration barrier (podocytes + endothelium)
Vasculature / EndotheliumGlomerular & peritubular capillaries
Hypertension
On-target loss of endothelial nitric oxide from VEGF-pathway blockade — so consistent it marks drug activity.
Mechanism of kidney injury
VEGFR2 tyrosine kinase inhibition reduces glomerular VEGF and nitric-oxide signaling, increasing vascular tone (hypertension) and potentially injuring the glomerular filtration barrier (proteinuria/podocytopathy). A clinically dominant non-renal hazard is QT prolongation, which interacts with drug-induced electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia) to raise arrhythmia risk.
Clinical presentation
New or worsening hypertension, sometimes with proteinuria; clinicians must also watch for QT prolongation and the electrolyte derangements (hypocalcemia, hypokalemia, hypomagnesemia) that compound cardiac risk.
Onset
Within the first weeks of therapy.
Reversibility
Reversible
Anticancer mechanism
Oral inhibitor of RET, VEGFR2 (and other VEGFRs) and EGFR signaling, blocking angiogenesis and oncogenic RET-driven proliferation. Approved for advanced/metastatic medullary thyroid carcinoma.
Management
Antihypertensive therapy (ACE inhibitor/ARB favored); interrupt or dose-reduce per label for grade 3 hypertension or significant proteinuria; aggressively maintain potassium, magnesium and calcium to mitigate QT-related arrhythmia. Hypertension is rarely dose-limiting and improves with treatment.
Risk factors
- Pre-existing hypertension
- Baseline proteinuria or CKD
- Electrolyte abnormalities (QT risk)
Prevention
- Baseline and periodic blood pressure, urine protein, ECG and electrolyte monitoring
- Blood pressure optimization and electrolyte repletion before and during therapy
Note · Hypertension is the principal renal-vascular signal; proteinuria is a class effect, and QT prolongation (a boxed warning) is the key non-renal safety concern that is amplified by renal electrolyte losses.
Clinical depth
Renal dose adjustment
Reduce the starting dose for moderate-to-severe renal impairment per label (e.g., 200 mg when CrCl < 50 mL/min) because vandetanib is partly renally excreted and exposure rises with impairment; titrate with ECG and electrolyte monitoring.
Dialyzability & ESKD dosing
Long half-life (~19 days), large volume of distribution and high protein binding make it essentially non-dialyzable; HD does not provide meaningful removal and is not used for dosing.
Differential diagnosis
VEGFR-TKI hypertension/proteinuria versus baseline nephropathy versus prerenal AKI. Crucially, separate drug-induced electrolyte wasting (which drives QT risk) from other causes, since correcting it is part of safe vandetanib use.
Monitoring
- Blood pressure regularly
- ECG (QTc) at baseline, 2-4 and 8-12 weeks, then periodically
- Serum potassium, magnesium, calcium and TSH
- Urine protein (dipstick/UPCR) periodically
Key trials & series
- ZETA phase III trial in advanced medullary thyroid carcinoma (hypertension 32% vs 5% placebo)
Clinical pearls
- Vandetanib's renal-vascular signal is hypertension, but the safety-defining toxicity is QT prolongation — monitor ECG and electrolytes together.
- Reduce the starting dose when CrCl < 50 mL/min, as it is partly renally cleared with a very long half-life.
- Hypomagnesemia/hypokalemia from VEGFR-TKI effects compound QT risk, so repletion is therapeutic and protective.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Glomerulus
Filtration barrier (podocytes + endothelium)
Injury signatures
HypertensionGlomerular Injury / Proteinuria
Beyond the kidney
Class-level context for the major non-renal toxicities of vegfr/egfr/ret tkis.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Hypertension, arterial/venous thrombosis, bleeding, impaired wound healing
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- LV dysfunction; QT (some TKIs)
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Diarrhea, perforation/fistula
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Hand-foot skin reaction
Evidence
5 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkVandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.Wells SA et al. · J Clin Oncol 2012 · PMID 22025146Pivotal ZETA trial reporting hypertension in 32% with vandetanib versus 5% with placebo.PMIDCabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect.Hojer Wang L et al. · Int J Mol Sci 2023 · PMID 36768635Reviews vandetanib treatment-related hypertension and its management.PMIDNephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update.Nervo A et al. · Crit Rev Oncol Hematol 2021 · PMID 34801702Reviews renal adverse events (proteinuria, hypertension) across thyroid-cancer TKIs.PMIDTherapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.Estrada CC et al. · J Am Soc Nephrol 2019 · PMID 30642877Mechanistic basis of VEGFR-TKI hypertension and glomerular proteinuria.PMIDThe Role of Angiogenesis Inhibitors in Hypertension: Following "Ariadne's Thread".Sanidas E et al. · Am J Hypertens 2018 · PMID 29788148Reviews antiangiogenic hypertension pathophysiology and management.
Related agents
Other agents sharing the same signature kidney injury.